An innovative biopharmaceutical company integrating antibody drug development, production and commercialization
Focusing on “clinical value”, AD Pharmaceuticals Co., Ltd. fully optimizes advantage resources and efficiently promotes the development and commercialization of innovative drugs, providing patients with better choices.
In response to unmet clinical needs worldwide,
we provide patients with safer and more effective health solutions.
We focus on a series of innovative drugs and combined therapies for cardiovascular disease, tumors and other major diseases.
Ebronucimab (PCSK9 monoclonal antibody, AK102)
Pulocimab (VEGFR-2 monoclonal antibody, AK109)
Latest News
- Clinical developmentNMPA accepted Ebronucimab (PCSK9) marketing application in two indications2023-06-02
- Company OperationAD Pharmaceuticals Puts China-Singapore Guangzhou Knowledge City Base into Operation2022-05-20
- Clinical developmentPatient Enrollment Completed Ahead of Schedule for Phase III Clinical Trial of Ebronucimab (PCSK9 Monoclonal Antibody)2021-12-22